The single most significant near-term opportunity is the genericization wave anticipated between 2026 and 2030, during which time the progressive expiry of Novo Nordisk's semaglutide patent portfolio across major markets will enable dozens of generic pharmaceutical companies to enter the semaglutide formulation market, each requiring third-party API supply
At a glance Status : Confirmed GLP-1 receptor agonist use (specific drug not publicly disclosed) Medical context : Pre-existing autoimmune thyroid condition requiring medication Timeline : Public confirmation in 2024 interviews Discontinuation status : Not publicly confirmed whether she has stopped or continues treatment Clinical focus of this page : What peer-reviewed evidence says about GLP-1 discontinuation, regain risk, and maintenance in patients with thyroid comorbidities The Discontinuation Problem: What the Trials Show The single most replicated finding in GLP-1 obesity research is that stopping the medication leads to weight regain
It is the first of these medications to interact with two hormones in the body, which is why researchers believe it manages blood sugar levels better than previous medicines and helps people lose more weight
Understanding why this happens can help put your mind at ease and ensure the best possible experience at our clinic
Semaglutide, a GLP-1 receptor agonist, has shown significant efficacy in promoting weight loss
